You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePhentermine
Accession NumberDB00191  (APRD00093)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA central nervous system stimulant and sympathomimetic with actions and uses similar to those of dextroamphetamine. It has been used most frequently in the treatment of obesity. [PubChem]. Some common brand names for phentermine are Adipex-P® and Suprenza™. Phentermine is also available in combination medications such as Qsymia®.
Structure
Thumb
Synonyms
alpha,alpha-Dimethylphenethylamine
Fentermina
Phenterminum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fastin Cap 30mgCapsule30 mgOralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1993-12-311999-02-02Canada
SuprenzaTablet, orally disintegrating15 mg/1OralAkrimax Pharmaceuticals, LLC2012-12-14Not applicableUs
SuprenzaTablet, orally disintegrating30 mg/1OralAkrimax Pharmaceuticals, LLC2012-12-14Not applicableUs
SuprenzaTablet, orally disintegrating37.5 mg/1OralAkrimax Pharmaceuticals, LLC2012-12-14Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Adipex-PTablet37.5 mg/1OralA S Medication Solutions Llc1990-09-30Not applicableUs
Adipex-PTablet37.5 mg/1OralA S Medication Solutions Llc1990-09-30Not applicableUs
Adipex-PTablet37.5 mg/1OralTeva Select Brands1990-09-30Not applicableUs
Adipex-PTablet37.5 mg/1OralPd Rx Pharmaceuticals, Inc.2011-02-14Not applicableUs
Adipex-PCapsule37.5 mg/1OralTeva Select Brands1990-09-30Not applicableUs
LomairaTablet8 mg/1OralKvk Tech, Inc.2016-09-12Not applicableUs
PhentermineCapsule15 mg/1OralAurolife Pharma, LLC2016-11-11Not applicableUs
PhentermineCapsule30 mg/1OralAurolife Pharma, LLC2016-11-11Not applicableUs
Phentermine HClCapsule30 mg/1OralDIRECT RX2016-07-11Not applicableUs
Phentermine HClCapsule15 mg/1OralDIRECT RX2016-07-08Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralPreferred Pharmaceuticals, Inc.2012-07-25Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralApotheca Inc.1999-11-08Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralKvk Tech, Inc.2012-08-07Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralRx Change Co.2014-11-21Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralA S Medication Solutions Llc2012-08-07Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralTAGI Pharma, Inc.2013-04-16Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralA S Medication Solutions Llc2012-08-15Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralProficient Rx LP2012-08-07Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralPd Rx Pharmaceuticals, Inc.1997-04-28Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1Oralbryant ranch prepack2002-01-04Not applicableUs
Phentermine HydrochlorideTablet30 mg/1OralNu Care Pharmaceuticals, Inc.2013-08-12Not applicableUs
Phentermine HydrochlorideCapsule37.5 mg/1OralLeading Pharma, Llc2015-02-25Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralDIRECT RX2014-01-01Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralTeva Pharmaceuticals USA Inc2011-10-03Not applicableUs
Phentermine HydrochlorideTablet30 mg/1OralBlenheim Pharmacal, Inc.2013-10-21Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralRebel Distributors Corp1983-02-03Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralLake Erie Medical DBA Quality Care Products2012-08-15Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralUnit Dose Services2005-04-15Not applicableUs
Phentermine HydrochlorideTablet30 mg/1OralMutual Pharmaceutical Company, Inc.2013-08-12Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralLannett Company, Inc.2012-01-20Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralAurolife Pharma, LLC2011-06-10Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralPd Rx Pharmaceuticals, Inc.2007-12-01Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralUnit Dose Services2003-10-23Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralH.J. Harkins Company, Inc.2007-12-01Not applicableUs
Phentermine HydrochlorideCapsule37.5 mg/1OralPhysicians Total Care, Inc.2011-07-29Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1Oralbryant ranch prepack1997-04-28Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralPreferred Pharmaceuticals Inc.2015-11-20Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralPreferred Pharmaceuticals, Inc.2012-03-05Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralLannett Company, Inc.2007-12-01Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralBlenheim Pharmacal, Inc.2010-05-17Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralAidarex Pharmaceuticals LLC2012-08-07Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralA S Medication Solutions Llc2012-08-07Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralUnit Dose Services2012-08-07Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralA S Medication Solutions Llc2012-08-15Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralMikah Pharma, Llc2014-05-01Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralRising Pharmaceuticals, Inc.2012-09-21Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralA S Medication Solutions2003-10-23Not applicableUs
Phentermine HydrochlorideCapsule37.5 mg/1OralLannett Company, Inc.2011-07-20Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralNu Care Pharmaceuticals, Inc.2003-10-23Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralPhysicians Total Care, Inc.2008-01-25Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralProficient Rx LP2005-04-15Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralKeltman Pharmaceuticals Inc.2007-07-31Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralPreferred Pharmaceuticals, Inc.2011-09-22Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralApotheca Inc.2002-08-12Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralKvk Tech, Inc.2012-08-07Not applicableUs
Phentermine HydrochlorideCapsule37.5 mg/1OralEpic Pharma, LLC2015-04-15Not applicableUs
Phentermine HydrochlorideCapsule37.5 mg/1OralA S Medication Solutions Llc2012-08-15Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralNorthwind Pharmaceuticals2014-05-15Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralUnit Dose Services2003-10-23Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralA S Medication Solutions Llc2012-08-07Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-08-07Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1Oralbryant ranch prepack2003-10-23Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralNu Care Pharmaceuticals, Inc.2012-08-07Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralLife Line Home Care Services, Inc.2008-03-31Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralQualitest Pharmaceuticals2002-01-042017-07-31Us
Phentermine HydrochlorideCapsule15 mg/1OralTeva Pharmaceuticals USA Inc2011-03-09Not applicableUs
Phentermine HydrochlorideCapsule37.5 mg/1OralBlenheim Pharmacal, Inc.2010-03-04Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralRebel Distributors Corp.2003-10-23Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralA S Medication Solutions Llc2012-08-07Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralBlenheim Pharmacal, Inc.2013-03-11Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralSTAT Rx USA LLC2007-12-01Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralPd Rx Pharmaceuticals, Inc.2011-03-08Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralUnit Dose Services2003-10-23Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralH.J. Harkins Company, Inc.2003-10-23Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralPd Rx Pharmaceuticals, Inc.2003-10-23Not applicableUs
Phentermine HydrochlorideCapsule37.5 mg/1Oralbryant ranch prepack2012-08-15Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralLeading Pharma, Llc2015-02-25Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralPd Rx Pharmaceuticals, Inc.2012-08-15Not applicableUs
Phentermine HydrochlorideTablet30 mg/1OralA S Medication Solutions2013-08-12Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralLannett Company, Inc.2007-12-01Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralKvk Tech, Inc.2012-08-15Not applicableUs
Phentermine HydrochlorideCapsule37.5 mg/1OralAidarex Pharmaceuticals LLC2012-08-15Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralA S Medication Solutions Llc2012-08-15Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralTAGI Pharma, Inc.2011-03-08Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralA S Medication Solutions Llc2012-08-07Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralProficient Rx LP2013-08-12Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralDispensing Solutions, Inc.1998-06-01Not applicableUs
Phentermine HydrochlorideTablet30 mg/1OralA S Medication Solutions2013-08-12Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralApotheca Inc.1998-06-01Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralPolygen Pharmaceuticals Inc.2016-11-18Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralA S Medication Solutions Llc2003-10-23Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralNorthwind Pharmaceuticals2014-06-01Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralPhysicians Total Care, Inc.1995-02-01Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1Oralbryant ranch prepack2002-01-04Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralLegacy Pharmaceutical Packaging2014-04-02Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralPreferred Pharmaceuticals, Inc.2014-11-10Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralIngenus Pharmaceuticals Nj, Llc2011-11-01Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralLannett Company, Inc.2010-07-19Not applicableUs
Phentermine HydrochlorideCapsule37.5 mg/1OralKvk Tech, Inc.2012-08-15Not applicableUs
Phentermine HydrochlorideCapsule37.5 mg/1OralPd Rx Pharmaceuticals, Inc.2012-08-15Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralCamber Pharmaceuticals, Inc.2014-04-02Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralUnit Dose Services2012-08-07Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1Oralbryant ranch prepack2010-07-19Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralA S Medication Solutions2013-04-16Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralPd Rx Pharmaceuticals, Inc.2012-08-07Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralEon Labs, Inc.1981-06-12Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralBlenheim Pharmacal, Inc.2010-03-04Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralBlenheim Pharmacal, Inc.2013-03-18Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralSTAT Rx USA LLC2003-10-23Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralPd Rx Pharmaceuticals, Inc.2005-04-15Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralUnit Dose Services2012-08-07Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralMutual Pharmaceutical Company, Inc.2003-10-23Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1Oralbryant ranch prepack2012-08-15Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralLeading Pharma, Llc2015-03-09Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralPreferred Pharmaceuticals, Inc.2014-08-25Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralLannett Company, Inc.2007-12-01Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralKvk Tech, Inc.2012-08-07Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralAidarex Pharmaceuticals LLC2012-08-15Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralA S Medication Solutions Llc2012-08-15Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralTAGI Pharma, Inc.2013-04-16Not applicableUs
Phentermine HydrochlorideCapsule37.5 mg/1OralA S Medication Solutions Llc2012-08-15Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralProficient Rx LP2003-10-23Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralDispensing Solutions, Inc.2003-10-23Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralPreferred Pharmaceuticals, Inc.2014-01-15Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralApotheca Inc.2003-10-23Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralA S Medication Solutions2003-10-23Not applicableUs
Phentermine HydrochlorideCapsule37.5 mg/1OralApotheca, Inc.1999-11-082016-10-13Us
Phentermine HydrochlorideTablet37.5 mg/1OralPd Rx Pharmaceuticals, Inc.2003-10-23Not applicableUs
Phentermine HydrochlorideTablet30 mg/1OralA S Medication Solutions Llc2013-08-12Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralNorthwind Pharmaceuticals2014-06-01Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralPhysicians Total Care, Inc.1997-04-28Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1Oralbryant ranch prepack2007-12-01Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralPreferred Pharmaceuticals Inc.2015-10-29Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralPreferred Pharmaceuticals, Inc.2014-12-22Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralPd Rx Pharmaceuticals, Inc.2013-04-16Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralLannett Company, Inc.2005-04-15Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralBlenheim Pharmacal, Inc.2009-12-30Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralAidarex Pharmaceuticals LLC2012-08-07Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralA S Medication Solutions Llc2007-12-01Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralUnit Dose Services1981-06-12Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralA S Medication Solutions Llc2012-08-07Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralElite Laboratories, Inc.2014-05-01Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralA S Medication Solutions2012-08-15Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralEon Labs, Inc.1981-06-12Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralEon Labs, Inc.1981-06-12Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralBlenheim Pharmacal, Inc.2009-12-21Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralRebel Distributors Corp1999-11-08Not applicableUs
Phentermine HydrochlorideTablet37.5 mg/1OralPd Rx Pharmaceuticals, Inc.2013-08-12Not applicableUs
Phentermine HydrochlorideCapsule37.5 mg/1OralUnit Dose Services2012-08-15Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralMutual Pharmaceutical Company, Inc.2003-10-23Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralPd Rx Pharmaceuticals, Inc.2012-08-07Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1Oralbryant ranch prepack2012-08-07Not applicableUs
Phentermine HydrochlorideCapsule30 mg/1OralLeading Pharma, Llc2015-03-09Not applicableUs
Phentermine HydrochlorideCapsule15 mg/1OralPreferred Pharmaceuticals, Inc.2012-08-07Not applicableUs
Phentermine Resin ERCapsule, extended release30 mg/1OralLannett Company, Inc.2011-07-28Not applicableUs
Phentermine Resin ERCapsule, extended release15 mg/1OralLannett Company, Inc.2011-07-28Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DuromineNot Available
FastinNot Available
IonaminNot Available
ObenixNot Available
Obestin-30Not Available
PhentercotNot Available
PhentrideNot Available
Pro-FastNot Available
TeramineNot Available
ZantrylNot Available
Brand mixtures
NameLabellerIngredients
QsymiaVIVUS, Inc.
Salts
Name/CASStructureProperties
Phentermine Hydrochloride
1197-21-3
Thumb
  • InChI Key: NCAIGTHBQTXTLR-UHFFFAOYSA-N
  • Monoisotopic Mass: 185.097127224
  • Average Mass: 185.694
DBSALT000138
Categories
UNIIC045TQL4WP
CAS number122-09-8
WeightAverage: 149.2328
Monoisotopic: 149.120449485
Chemical FormulaC10H15N
InChI KeyDHHVAGZRUROJKS-UHFFFAOYSA-N
InChI
InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3
IUPAC Name
2-methyl-1-phenylpropan-2-amine
SMILES
CC(C)(N)CC1=CC=CC=C1
Pharmacology
IndicationFor the treatment and management of obesity.
Structured Indications
PharmacodynamicsPhentermine is indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction. Phentermine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.
Mechanism of actionPhentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse.Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent noradrenaline transporterProteinyes
inhibitor
HumanP23975 details
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
Sodium-dependent dopamine transporterProteinyes
inhibitor
HumanQ01959 details
Amine oxidase [flavin-containing] AProteinyes
antagonist
HumanP21397 details
Amine oxidase [flavin-containing] BProteinyes
antagonist
HumanP27338 details
Related Articles
AbsorptionPhentermine is rapidly absorbed after oral ingestion.
Volume of distributionNot Available
Protein bindingApproximately 96.3%
Metabolism

Hepatic.

Route of eliminationNot Available
Half life16 to 31 hours
ClearanceNot Available
ToxicityLD50 is adult monkeys is 15 to 20 mg/kg. Symptoms of overdose include delirium, mania, self-injury, marked hypertension, tachycardia, arrhythmia, hyperpyrexia, convulsion, coma, and circulatory collapse.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypertensive activities of Phentermine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Phentermine is combined with Acebutolol.Approved
AcepromazineAcepromazine may decrease the stimulatory activities of Phentermine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Phentermine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Phentermine.Approved
AcrivastinePhentermine may decrease the sedative activities of Acrivastine.Approved
AlcaftadinePhentermine may decrease the sedative activities of Alcaftadine.Approved
AlfentanilPhentermine may increase the analgesic activities of Alfentanil.Approved, Illicit
AlimemazinePhentermine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlphacetylmethadolPhentermine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
Aluminum phosphateAluminum phosphate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
AmineptineAmineptine may increase the stimulatory activities of Phentermine.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of Phentermine.Approved, Investigational
AmitriptylineAmitriptyline may increase the stimulatory activities of Phentermine.Approved
Ammonium chlorideThe serum concentration of Phentermine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of Phentermine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Phentermine.Approved, Illicit
AntazolinePhentermine may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of Phentermine.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of Phentermine.Approved
AstemizolePhentermine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AtomoxetineAtomoxetine may increase the hypertensive activities of Phentermine.Approved
AzaperoneAzaperone may decrease the stimulatory activities of Phentermine.Vet Approved
AzatadinePhentermine may decrease the sedative activities of Azatadine.Approved
AzelastinePhentermine may decrease the sedative activities of Azelastine.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Phentermine.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Phentermine.Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Phentermine is combined with Benzphetamine.Approved, Illicit
BezitramidePhentermine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Phentermine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Phentermine.Approved
BromperidolBromperidol may decrease the stimulatory activities of Phentermine.Investigational
BrompheniraminePhentermine may decrease the sedative activities of Brompheniramine.Approved
BucindololThe risk or severity of adverse effects can be increased when Phentermine is combined with Bucindolol.Investigational
BuclizinePhentermine may decrease the sedative activities of Buclizine.Approved
BuprenorphinePhentermine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
Butanoic AcidPhentermine may decrease the sedative activities of Butanoic Acid.Experimental
ButorphanolPhentermine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Calcium carbonateCalcium carbonate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
CarbinoxaminePhentermine may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilPhentermine may increase the analgesic activities of Carfentanil.Illicit, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Phentermine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Phentermine.Withdrawn
CeliprololThe risk or severity of adverse effects can be increased when Phentermine is combined with Celiprolol.Approved, Investigational
CetirizinePhentermine may decrease the sedative activities of Cetirizine.Approved
ChloropyraminePhentermine may decrease the sedative activities of Chloropyramine.Approved
ChlorphenaminePhentermine may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxaminePhentermine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorphentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Phentermine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Phentermine.Approved, Withdrawn
CimetidinePhentermine may decrease the sedative activities of Cimetidine.Approved
CinnarizinePhentermine may decrease the sedative activities of Cinnarizine.Approved
ClemastinePhentermine may decrease the sedative activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Phentermine is combined with Clenbuterol.Approved, Vet Approved
ClomipramineClomipramine may increase the stimulatory activities of Phentermine.Approved, Vet Approved
ClozapineClozapine may decrease the stimulatory activities of Phentermine.Approved
CodeinePhentermine may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of Phentermine.Approved
CyclizinePhentermine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of Phentermine.Approved
CyproheptadinePhentermine may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Phentermine.Approved
DesipramineDesipramine may increase the stimulatory activities of Phentermine.Approved
DesloratadinePhentermine may decrease the sedative activities of Desloratadine.Approved, Investigational
DexbrompheniraminePhentermine may decrease the sedative activities of Dexbrompheniramine.Approved
Dexchlorpheniramine maleatePhentermine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextromoramidePhentermine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxyphenePhentermine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocinePhentermine may increase the analgesic activities of Dezocine.Approved
DiclofenamideDiclofenamide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
DihydrocodeinePhentermine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroetorphinePhentermine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphinePhentermine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinatePhentermine may decrease the sedative activities of Dimenhydrinate.Approved
DimetindenePhentermine may decrease the sedative activities of Dimetindene.Approved
DimetotiazinePhentermine may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydraminePhentermine may decrease the sedative activities of Diphenhydramine.Approved
DiphenoxylatePhentermine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DobutamineThe risk or severity of adverse effects can be increased when Phentermine is combined with Dobutamine.Approved
DopamineThe risk or severity of adverse effects can be increased when Phentermine is combined with Dopamine.Approved
DosulepinDosulepin may increase the stimulatory activities of Phentermine.Approved
DoxepinPhentermine may decrease the sedative activities of Doxepin.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Phentermine is combined with Doxofylline.Approved
DoxylaminePhentermine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPEPhentermine may increase the analgesic activities of DPDPE.Investigational
DronabinolDronabinol may increase the tachycardic activities of Phentermine.Approved, Illicit
DroperidolDroperidol may decrease the stimulatory activities of Phentermine.Approved, Vet Approved
EbastinePhentermine may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of Phentermine.Investigational
EmedastinePhentermine may decrease the sedative activities of Emedastine.Approved
EphedrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Ephedrine.Approved
EpinastinePhentermine may decrease the sedative activities of Epinastine.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Epinephrine.Approved, Vet Approved
EsmirtazapinePhentermine may decrease the sedative activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Phentermine.Approved
EthopropazinePhentermine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Phentermine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Phentermine which could result in a higher serum level.Withdrawn
EthylmorphinePhentermine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtilefrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Etilefrine.Withdrawn
EtorphinePhentermine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidinePhentermine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Phentermine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Phentermine is combined with Fenoterol.Approved
FentanylPhentermine may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Phentermine.Approved
FexofenadinePhentermine may decrease the sedative activities of Fexofenadine.Approved
FlunarizinePhentermine may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Phentermine.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Phentermine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Phentermine.Approved
FurazolidoneFurazolidone may increase the hypertensive activities of Phentermine.Approved, Vet Approved
GuanethidineThe serum concentration of Phentermine can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of Phentermine.Approved
HeroinPhentermine may increase the analgesic activities of Heroin.Approved, Illicit
HexamethylenetetramineThe serum concentration of Phentermine can be decreased when it is combined with Hexamethylenetetramine.Approved, Vet Approved
HydracarbazineHydracarbazine may increase the hypertensive activities of Phentermine.Approved
HydrocodonePhentermine may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphonePhentermine may increase the analgesic activities of Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideThe risk or severity of adverse effects can be increased when Phentermine is combined with Hydroxyamphetamine hydrobromide.Approved
HydroxyzinePhentermine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Phentermine.Approved
ImipramineImipramine may increase the stimulatory activities of Phentermine.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Phentermine.Approved
Ioflupane I-123Phentermine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideIproclozide may increase the hypertensive activities of Phentermine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Phentermine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Phentermine.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Phentermine is combined with Isoprenaline.Approved
IsothipendylPhentermine may decrease the sedative activities of Isothipendyl.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Phentermine is combined with Isoxsuprine.Approved, Withdrawn
Kct 0809Phentermine may decrease the sedative activities of Kct 0809.Investigational
KetobemidonePhentermine may increase the analgesic activities of Ketobemidone.Approved
KetotifenPhentermine may decrease the sedative activities of Ketotifen.Approved
L-Glutamic AcidThe serum concentration of Phentermine can be decreased when it is combined with L-Glutamic Acid.Nutraceutical
LabetalolThe risk or severity of adverse effects can be increased when Phentermine is combined with Labetalol.Approved
LevocabastinePhentermine may decrease the sedative activities of Levocabastine.Approved
LevocetirizinePhentermine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetatePhentermine may increase the analgesic activities of Levomethadyl Acetate.Approved
LevorphanolPhentermine may increase the analgesic activities of Levorphanol.Approved
LinezolidLinezolid may increase the hypertensive activities of Phentermine.Approved, Investigational
LithiumLithium may decrease the stimulatory activities of Phentermine.Approved
LodoxamidePhentermine may decrease the sedative activities of Lodoxamide.Approved
LofentanilPhentermine may increase the analgesic activities of Lofentanil.Illicit
LoratadinePhentermine may decrease the sedative activities of Loratadine.Approved
LoxapineLoxapine may decrease the stimulatory activities of Phentermine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Phentermine.Approved
MagaldrateMagaldrate may decrease the excretion rate of Phentermine which could result in a higher serum level.Withdrawn
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of Phentermine.Withdrawn
MeclizinePhentermine may decrease the sedative activities of Meclizine.Approved
MelperoneMelperone may decrease the stimulatory activities of Phentermine.Approved
MephentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Mephentermine.Approved
MepyraminePhentermine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazinePhentermine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Phentermine.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Phentermine is combined with Metaraminol.Approved, Investigational
MethadonePhentermine may increase the analgesic activities of Methadone.Approved
Methadyl AcetatePhentermine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Phentermine is combined with Methamphetamine.Approved, Illicit
MethapyrilenePhentermine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Phentermine.Approved
MethoxamineThe risk or severity of adverse effects can be increased when Phentermine is combined with Methoxamine.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Phentermine.Investigational
MetiamidePhentermine may decrease the sedative activities of Metiamide.Experimental
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Phentermine.Approved, Investigational
MianserinPhentermine may decrease the sedative activities of Mianserin.Approved
MidodrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Midodrine.Approved
MinaprineMinaprine may increase the hypertensive activities of Phentermine.Approved
MirtazapinePhentermine may decrease the sedative activities of Mirtazapine.Approved
MizolastinePhentermine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Phentermine.Approved
MolindoneMolindone may decrease the stimulatory activities of Phentermine.Approved
MorphinePhentermine may increase the analgesic activities of Morphine.Approved, Investigational
NabiloneNabilone may increase the tachycardic activities of Phentermine.Approved, Investigational
NalbuphinePhentermine may increase the analgesic activities of Nalbuphine.Approved
NialamideNialamide may increase the hypertensive activities of Phentermine.Withdrawn
NizatidinePhentermine may decrease the sedative activities of Nizatidine.Approved
NorepinephrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Norepinephrine.Approved
NormethadonePhentermine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the stimulatory activities of Phentermine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Phentermine is combined with Nylidrin.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Phentermine.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Phentermine.Approved, Investigational
OlopatadinePhentermine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Phentermine.Approved
OpipramolOpipramol may increase the stimulatory activities of Phentermine.Investigational
OpiumPhentermine may increase the analgesic activities of Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Phentermine is combined with Orciprenaline.Approved
OsanetantOsanetant may decrease the stimulatory activities of Phentermine.Investigational
OxycodonePhentermine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineThe risk or severity of adverse effects can be increased when Phentermine is combined with Oxymetazoline.Approved
OxymorphonePhentermine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
PaliperidonePaliperidone may decrease the stimulatory activities of Phentermine.Approved
PargylinePargyline may increase the hypertensive activities of Phentermine.Approved
PemirolastPhentermine may decrease the sedative activities of Pemirolast.Approved
PentazocinePhentermine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Phentermine.Investigational
PerospironePerospirone may decrease the stimulatory activities of Phentermine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Phentermine.Approved
PethidinePhentermine may increase the analgesic activities of Pethidine.Approved
PhenelzinePhenelzine may increase the hypertensive activities of Phentermine.Approved
PhenindaminePhentermine may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Phentermine.Withdrawn
PheniraminePhentermine may decrease the sedative activities of Pheniramine.Approved
PhenmetrazineThe risk or severity of adverse effects can be increased when Phentermine is combined with Phenmetrazine.Approved, Illicit
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Phentermine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Phentermine.Withdrawn
PhenylephrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phentermine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Phentermine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Phentermine.Approved
PipamperonePipamperone may decrease the stimulatory activities of Phentermine.Approved
PipotiazinePipotiazine may decrease the stimulatory activities of Phentermine.Approved
PiritramidePhentermine may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Phentermine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Phentermine.Withdrawn
ProcaterolThe risk or severity of adverse effects can be increased when Phentermine is combined with Procaterol.Approved
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Phentermine.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of Phentermine.Approved, Vet Approved
PromethazinePhentermine may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of Phentermine.Approved
ProthipendylProthipendyl may decrease the stimulatory activities of Phentermine.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of Phentermine.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Pseudoephedrine.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of Phentermine.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Racepinephrine.Approved
RacloprideRaclopride may decrease the stimulatory activities of Phentermine.Investigational
RanitidinePhentermine may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of Phentermine.Approved
RemifentanilPhentermine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Phentermine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Phentermine.Approved
RisperidoneRisperidone may decrease the stimulatory activities of Phentermine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Phentermine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Ritodrine.Approved
Roxatidine acetatePhentermine may decrease the sedative activities of Roxatidine acetate.Approved
SafrazineSafrazine may increase the hypertensive activities of Phentermine.Withdrawn
SelegilineSelegiline may increase the hypertensive activities of Phentermine.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Phentermine.Approved, Withdrawn
Spaglumic AcidPhentermine may decrease the sedative activities of Spaglumic Acid.Approved
SufentanilPhentermine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Phentermine.Approved
SynephrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Synephrine.Experimental
TapentadolPhentermine may increase the analgesic activities of Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Phentermine.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Phentermine is combined with Terbutaline.Approved
TerfenadinePhentermine may decrease the sedative activities of Terfenadine.Withdrawn
TesmilifenePhentermine may decrease the sedative activities of Tesmilifene.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Phentermine is combined with Tetryzoline.Approved
ThioproperazineThioproperazine may decrease the stimulatory activities of Phentermine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Phentermine.Approved
ThiothixeneThiothixene may decrease the stimulatory activities of Phentermine.Approved
ThonzylaminePhentermine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of Phentermine.Approved
TiaprideTiapride may decrease the stimulatory activities of Phentermine.Investigational
ToloxatoneToloxatone may increase the hypertensive activities of Phentermine.Approved
TramadolPhentermine may increase the analgesic activities of Tramadol.Approved, Investigational
TranilastPhentermine may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Phentermine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Phentermine.Approved
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Phentermine.Approved
TriflupromazineTriflupromazine may decrease the stimulatory activities of Phentermine.Approved, Vet Approved
TrimipramineTrimipramine may increase the stimulatory activities of Phentermine.Approved
TripelennaminePhentermine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidinePhentermine may decrease the sedative activities of Triprolidine.Approved
TyramineThe risk or severity of adverse effects can be increased when Phentermine is combined with Tyramine.Investigational, Nutraceutical
Vitamin CThe serum concentration of Phentermine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneZiprasidone may decrease the stimulatory activities of Phentermine.Approved
ZotepineZotepine may decrease the stimulatory activities of Phentermine.Approved
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Phentermine.Approved, Investigational
Food Interactions
  • Limit caffeine intake.
  • Take without regard to meals.
References
Synthesis ReferenceNot Available
General References
  1. Bray GA: A concise review on the therapeutics of obesity. Nutrition. 2000 Oct;16(10):953-60. [PubMed:11054601 ]
  2. Nelson DL, Gehlert DR: Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine. 2006 Feb;29(1):49-60. [PubMed:16622292 ]
External Links
ATC CodesA08AA01
AHFS Codes
  • 28:20.92
PDB EntriesNot Available
FDA labelDownload (159 KB)
MSDSDownload (48.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier+0.959
Caco-2 permeable+0.7688
P-glycoprotein substrateNon-substrate0.6477
P-glycoprotein inhibitor INon-inhibitor0.934
P-glycoprotein inhibitor IINon-inhibitor0.9801
Renal organic cation transporterNon-inhibitor0.8236
CYP450 2C9 substrateNon-substrate0.8411
CYP450 2D6 substrateSubstrate0.7204
CYP450 3A4 substrateNon-substrate0.6493
CYP450 1A2 substrateNon-inhibitor0.7962
CYP450 2C9 inhibitorNon-inhibitor0.8861
CYP450 2D6 inhibitorInhibitor0.7825
CYP450 2C19 inhibitorNon-inhibitor0.8996
CYP450 3A4 inhibitorNon-inhibitor0.7348
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8782
Ames testNon AMES toxic0.9681
CarcinogenicityNon-carcinogens0.6949
BiodegradationNot ready biodegradable0.9303
Rat acute toxicity2.8400 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9867
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Baxter healthcare corp anesthesia critical care
  • Teva pharmaceuticals usa inc
  • Glaxosmithkline
  • Ferndale laboratories inc
  • Shire richwood inc
  • Mm mast and co
  • Abc holding corp
  • Able laboratories inc
  • Actavis totowa llc
  • Barr laboratories inc
  • Camall co inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Ivax pharmaceuticals inc
  • Kvk tech inc
  • Lannett co inc
  • Lannett holdings inc
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Tg united inc
  • Tg united labs llc
  • Usl pharma inc
  • Vitarine pharmaceuticals inc
  • Watson laboratories inc
  • Actavis elizabeth llc
  • Caraco pharmaceutical laboratories ltd
  • Vintage pharmaceuticals inc
  • Solvay pharmaceuticals
  • Ucb inc
  • Quantum pharmics ltd
Packagers
Dosage forms
FormRouteStrength
CapsuleOral30 mg
TabletOral8 mg/1
CapsuleOral15 mg/1
CapsuleOral30 mg/1
CapsuleOral37.5 mg/1
TabletOral30 mg/1
TabletOral37.5 mg/1
Capsule, extended releaseOral15 mg/1
Capsule, extended releaseOral30 mg/1
Capsule, extended releaseOral
Tablet, orally disintegratingOral15 mg/1
Tablet, orally disintegratingOral30 mg/1
Tablet, orally disintegratingOral37.5 mg/1
Prices
Unit descriptionCostUnit
Phentermine hcl powder10.71USD g
Ionamin 30 mg capsule sa2.87USD capsule
Adipex-P 37.5 mg capsule2.2USD capsule
Adipex-p 37.5 mg tablet2.15USD tablet
Phentermine 37.5 mg tablet1.54USD tablet
Phentermine HCl 15 mg capsule1.18USD capsule
Phentermine HCl 30 mg capsule1.17USD capsule
Ionamin 15 mg capsule sa1.15USD capsule
Phentermine HCl 37.5 mg capsule1.0USD capsule
Phentermine HCl 37.5 mg tablet1.0USD tablet
Phentermine 8 mg tablet0.54USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6071537 No1997-06-232017-06-23Us
US6149938 No1998-07-232018-07-23Us
US7056890 No2000-06-142020-06-14Us
US7553818 No2000-06-142020-06-14Us
US7659256 No2000-06-142020-06-14Us
US7674776 No2000-06-142020-06-14Us
US8440170 No2009-03-142029-03-14Us
US8580298 No2009-05-152029-05-15Us
US8580299 No2009-06-142029-06-14Us
US8895057 No2008-06-092028-06-09Us
US8895058 No2008-06-092028-06-09Us
US9011905 No2008-06-092028-06-09Us
US9011906 No2008-06-092028-06-09Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point205 °CNot Available
water solubility18.6 g/LNot Available
logP1.90HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.757 mg/mLALOGPS
logP2.32ALOGPS
logP2.08ChemAxon
logS-2.3ALOGPS
pKa (Strongest Basic)10.25ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity48.34 m3·mol-1ChemAxon
Polarizability17.87 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.33 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-0ue9-0900000000-f2eb273dfd0ec45869c5View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0f89-2900000000-f527ee48b9e2784c178cView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0159-4900000000-548f73a83354267c9f81View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0002-0900000000-c7ab0aa268d14ae3da39View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-0002-1900000000-ce1c08c021fbc1cc5c8cView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-001i-2900000000-94b2b38953d359938c0aView in MoNA
MSMass Spectrum (Electron Ionization)splash10-0a4i-9100000000-7037d3f1fad22de72c33View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenylpropane
  • Aralkylamine
  • Hydrocarbon derivative
  • Primary amine
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Stephens LC, Katz SG: Phentermine and anaesthesia. Anaesth Intensive Care. 2005 Aug;33(4):525-7. [PubMed:16119498 ]
  4. Samanin R, Garattini S: Neurochemical mechanism of action of anorectic drugs. Pharmacol Toxicol. 1993 Aug;73(2):63-8. [PubMed:7902561 ]
  5. Proietto J, Fam BC, Ainslie DA, Thorburn AW: Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26. [PubMed:11060745 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. John CE, Jones SR: Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices. Neuropharmacology. 2007 Jun;52(8):1596-605. Epub 2007 Mar 16. [PubMed:17459426 ]
  2. Johnson GJ, Leis LA, Dunlop PC, Weir EK: The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux. J Thromb Haemost. 2003 Dec;1(12):2663-8. [PubMed:14675103 ]
  3. Mekontso-Dessap A, Brouri F, Pascal O, Lechat P, Hanoun N, Lanfumey L, Seif I, Benhaiem-Sigaux N, Kirsch M, Hamon M, Adnot S, Eddahibi S: Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation. 2006 Jan 3;113(1):81-9. Epub 2005 Dec 27. [PubMed:16380550 ]
  4. Rothman RB, Ayestas MA, Dersch CM, Baumann MH: Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation. 1999 Aug 24;100(8):869-75. [PubMed:10458725 ]
  5. Zolkowska D, Rothman RB, Baumann MH: Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther. 2006 Aug;318(2):604-10. Epub 2006 Apr 27. [PubMed:16644904 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. John CE, Jones SR: Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices. Neuropharmacology. 2007 Jun;52(8):1596-605. Epub 2007 Mar 16. [PubMed:17459426 ]
  2. Gruner JA, Marcy VR, Lin YG, Bozyczko-Coyne D, Marino MJ, Gasior M: The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents. Sleep. 2009 Nov;32(11):1425-38. [PubMed:19928382 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Rothman RB: Is phentermine an inhibitor of monoamine oxidase? A critical appraisal. Synapse. 1999 May;32(2):141-5. [PubMed:10231134 ]
  2. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660 ]
  3. Kilpatrick IC, Traut M, Heal DJ: Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. Int J Obes Relat Metab Disord. 2001 Oct;25(10):1454-8. [PubMed:11673765 ]
  4. Nandigama RK, Newton-Vinson P, Edmondson DE: Phentermine inhibition of recombinant human liver monoamine oxidases A and B. Biochem Pharmacol. 2002 Mar 1;63(5):865-9. [PubMed:11911838 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Rothman RB: Does phentermine inhibit monoamine oxidase? Lancet. 1999 Apr 17;353(9161):1362-3. [PubMed:10218558 ]
  2. Rothman RB: Is phentermine an inhibitor of monoamine oxidase? A critical appraisal. Synapse. 1999 May;32(2):141-5. [PubMed:10231134 ]
  3. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660 ]
  4. Kilpatrick IC, Traut M, Heal DJ: Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. Int J Obes Relat Metab Disord. 2001 Oct;25(10):1454-8. [PubMed:11673765 ]
  5. Nandigama RK, Newton-Vinson P, Edmondson DE: Phentermine inhibition of recombinant human liver monoamine oxidases A and B. Biochem Pharmacol. 2002 Mar 1;63(5):865-9. [PubMed:11911838 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Nandigama RK, Newton-Vinson P, Edmondson DE: Phentermine inhibition of recombinant human liver monoamine oxidases A and B. Biochem Pharmacol. 2002 Mar 1;63(5):865-9. [PubMed:11911838 ]
  2. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Nandigama RK, Newton-Vinson P, Edmondson DE: Phentermine inhibition of recombinant human liver monoamine oxidases A and B. Biochem Pharmacol. 2002 Mar 1;63(5):865-9. [PubMed:11911838 ]
  2. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:40